The value of early detection of type 2 diabetes

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 16, Issue 2, 2009, Pages 95-99

  Colagiuri, Stephen ^a   Davies, Daniel ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Early detection; Screening; Type 2 diabetes

Indexed keywords

ARTERY DISEASE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIET; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; RETINOPATHY; REVIEW; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; ECONOMICS; HEALTH CARE DELIVERY;

DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 66149149526     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328329302f     Document Type: Review

References (47)

1. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
2. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.
3. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-853.
4. Lauritzen T, Griffin S, Borch-Johnsen K, et al. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening. Int J Obes Relat Metab Disord 2000; 24 (Suppl 3):S6-S11. Provides an overview of details of the ADDITION study.
5. IDF. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006.
6. DECODE. Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354:617-621.
7. Nakagami T, Qiao Q, Tuomilehto J, et al. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. Eur J Cardiovasc Prev Rehabil 2006; 13:555-561.
8. Barnett KN, McMurdo MET, Ogston SA, et al. Mortality in people diagnosed with type 2 diabetes at an older age: a systematic review. Age Ageing 2006; 35:463-468.
9. Tapp RJ, Shaw JE, de Courten MP, et al. Foot complications in type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20: 105-113.
10. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004; 44:792-798.
11. Spijkerman AMW, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 2003; 26:2604-2608.
12. Spijkerman AMW, Henry RMA, Dekker JM, et al. Prevalence of macrovascular disease amongst type 2 diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn Screening Study. J Intern Med 2004; 256:429-436.
13. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7yrs before clinical diagnosis. Diabetes Care 1992; 15:815-818.
14. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
15. Sandbaek A, Griffin SJ, Rutten G, et al. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia 2008; 51:1127-1134. Provides details of the ADDITION cohort and coronary heart disease risk.
16. Schellhase KG, Koepsell TD, Weiss NS, et al. Glucose screening and the risk of complications in type 2 diabetes mellitus. J Clin Epidemiol 2003; 56:75-80.
17. Schneider H, Ehrlich M, Lischinnski M. Did the intensive glycosuria screening of the sixties and seventies in East Germany improve the survival prognosis of early detected diabetics? Diabetes Stoffwechsel 1996; 5 (Suppl):33-38.
18. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002; 25:1410-1417.
19. Narayan KM, Thompson TJ, Boyle JP, et al. The use of population attributable risk to estimate the impact of prevention and early detection of type 2 diabetes on population-wide mortality risk in US males. Healthcare Manag Sci 1999; 2:223-227.
20. Kuo HS, Chang HJ, Chou P, et al. A Markov chain model to assess the efficacy of screening for noninsulin dependent diabetes mellitus (NIDDM). Int J Epidemiol 1999; 28:233-240.
21. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.
22. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
23. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
24. WHO. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Geneva: World Health Organization; 2006.
25. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796-2803.
26. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359:2072-2077.
27. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096-1105.
28. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-1156.
29. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67:152-162.
30. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537-544.
31. Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49:289-297.
32. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155-161.
33. NHMRC. National evidence based guidelines for the management of type 2 diabetes mellitus. Canberra: National Health and Medical Research Council; 2001.
34. ADA. Standards of medical care in diabetes - 2009. Diabetes Care 2009; 32 (Suppl 1):S13-S61.
35. Edelman D, Olsen MK, Dudley TK, et al. Impact of diabetes screening on quality of life. Diabetes Care 2002; 25:1022-1026.
36. Adriaanse MC, Snoek FJ. The psychological impact of screening for type 2 diabetes. Diabetes Metab Res Rev 2006; 22:20-25.
37. Eborall H, Davies R, Kinmonth A-L, et al. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335:490. Reports the actual experience of people participating in a screening program for diabetes.
38. Eborall HC, Griffin SJ, Prevost AT, et al. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335:486. Addresses the potential negative impact of screening for undiagnosed diabetes.
39. Skinner TC, Davies MJ, Farooqi AM, et al. Diabetes screening anxiety and beliefs. Diabet Med 2005; 22:1497-1502.
40. WHO. Screening for type 2 diabetes: report of a World Health Organization and International Diabetes Federation meeting. Geneva: World Health Organization; 2003.
41. Colagiuri S, Hussain Z, Zimmet P, et al. Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care 2004; 27:367-371.
42. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age. Diabetes Care 2005; 28:307-311.
43. Gulliford MC, Latinovic R, Charlton J. Diabetes diagnosis, resource utilization, and health outcomes. Am J Manag Care 2008; 14:32-38.
44. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146:473-481.
45. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000; 23:1563-1580.
46. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 336:1180-1185. Models screening and prevention scenarios in the UK setting.
47. Colagiuri S, Walker AE. Using an economic model of diabetes to evaluate prevention and care strategies in Australia. Health Aff (Millwood) 2008; 27:256-268. Models screening and prevention scenarios in the Australian setting.